BR112013013659B8 - Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia - Google Patents

Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia

Info

Publication number
BR112013013659B8
BR112013013659B8 BR112013013659A BR112013013659A BR112013013659B8 BR 112013013659 B8 BR112013013659 B8 BR 112013013659B8 BR 112013013659 A BR112013013659 A BR 112013013659A BR 112013013659 A BR112013013659 A BR 112013013659A BR 112013013659 B8 BR112013013659 B8 BR 112013013659B8
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutical composition
cancer
leukemia
epigenetic enzyme
Prior art date
Application number
BR112013013659A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013013659A2 (pt
BR112013013659B1 (pt
Inventor
James Olhava Edward
Wayne Kuntz Kevin
Richard Chesworth
Macfarlane Pollock Roy
Richard Daigle Scott
Marie Richon Victoria
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of BR112013013659A2 publication Critical patent/BR112013013659A2/pt
Publication of BR112013013659B1 publication Critical patent/BR112013013659B1/pt
Publication of BR112013013659B8 publication Critical patent/BR112013013659B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
BR112013013659A 2010-12-03 2011-12-02 Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia BR112013013659B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41966110P 2010-12-03 2010-12-03
US62/419,661 2010-12-03
PCT/US2011/063044 WO2012075381A1 (en) 2010-12-03 2011-12-02 Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes

Publications (3)

Publication Number Publication Date
BR112013013659A2 BR112013013659A2 (pt) 2016-09-06
BR112013013659B1 BR112013013659B1 (pt) 2022-06-21
BR112013013659B8 true BR112013013659B8 (pt) 2024-02-27

Family

ID=45444712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013659A BR112013013659B8 (pt) 2010-12-03 2011-12-02 Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia

Country Status (18)

Country Link
US (5) US8580762B2 (enExample)
EP (1) EP2646444B1 (enExample)
JP (1) JP5931905B2 (enExample)
KR (1) KR101923746B1 (enExample)
CN (1) CN103391939B (enExample)
AR (1) AR084408A1 (enExample)
AU (1) AU2011336415B2 (enExample)
BR (1) BR112013013659B8 (enExample)
CA (1) CA2819648C (enExample)
DK (1) DK2646444T3 (enExample)
ES (1) ES2577027T3 (enExample)
HR (1) HRP20160655T1 (enExample)
IL (1) IL226651A (enExample)
MX (1) MX2013006251A (enExample)
RU (1) RU2606514C2 (enExample)
SI (1) SI2646444T1 (enExample)
TW (1) TWI537271B (enExample)
WO (1) WO2012075381A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580762B2 (en) * 2010-12-03 2013-11-12 Epizyme, Inc. Substituted purine and 7-deazapurine compounds
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
CA2819625A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2011336264A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds
WO2013055397A1 (en) 2011-10-14 2013-04-18 Children's Medical Center Corporation Inhibition and enhancement of reprogramming by chromatin modifying enzymes
SI2794627T1 (sl) 2011-12-22 2019-02-28 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
CA2883781A1 (en) 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
WO2014100662A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Dot1 l inhibitors for use in the treatment of leukemia
EP2958921B1 (en) 2013-02-22 2017-09-20 Pfizer Inc Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus kinases (jak)
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
AU2014260433A1 (en) 2013-03-14 2015-09-10 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
SG11201506972PA (en) 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
JP2016517434A (ja) * 2013-03-14 2016-06-16 エピザイム，インコーポレイティド 癌を処置するための併用療法
US20160031839A1 (en) 2013-03-14 2016-02-04 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014152261A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Substituted 7-deazapurine compounds
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
AU2014239516B2 (en) * 2013-03-15 2019-01-24 Epizyme, Inc. Injectable formulations for treating cancer
CA2903303A1 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
WO2015003131A1 (en) * 2013-07-03 2015-01-08 Epizyme, Inc. Substituted purine compounds
US9535067B2 (en) 2013-07-29 2017-01-03 Dana-Farber Cancer Institute, Inc. DOT1L probes
US10407732B2 (en) 2013-08-02 2019-09-10 Memorial Sloan Kettering Cancer Center Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition
WO2015073706A1 (en) * 2013-11-13 2015-05-21 Epizyme, Inc. Methods for treating cancer
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
WO2016025635A2 (en) * 2014-08-13 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
US9458165B2 (en) 2014-08-27 2016-10-04 Dana-Farber Cancer Institute, Inc. DOT1L inhibitors
AU2015317509A1 (en) * 2014-09-17 2017-03-16 Epizyme, Inc. Injectable formulations for treating cancer
WO2016043874A2 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Combination therapy for treating cancer
EP3200826B1 (en) * 2014-09-30 2021-04-21 Vecht-lifshitz, Susan Eve Pharmaceutical compositions for treating ebola virus disease
US20180028552A1 (en) * 2015-01-30 2018-02-01 Epizyme, Inc. Combination therapy for treating cancer
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CA3012649A1 (en) 2016-01-26 2017-08-03 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia
KR102646126B1 (ko) 2016-03-15 2024-03-11 오리존 지노믹스 에스.에이. 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
CN106432095B (zh) * 2016-09-09 2019-04-16 东南大学 匹莫苯丹关键中间体6-(3,4-二氨基苯基)-5-甲基-4,5-二氢哒嗪-3(2h)-酮的制备
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
CN109748944B (zh) * 2017-11-03 2021-12-10 中国科学院上海药物研究所 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途
CN109748943A (zh) * 2017-11-03 2019-05-14 中国科学院上海药物研究所 2’-c-甲基取代核苷类化合物及其制备与用途
WO2019112719A1 (en) * 2017-12-05 2019-06-13 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
KR102118891B1 (ko) 2018-10-04 2020-06-04 성균관대학교산학협력단 매소니아노사이드 b를 유효성분으로 포함하는 혼합 직계성 백혈병 유전자 재배열 동반 백혈병 예방 및 치료용 약학적 조성물
EP3908583A4 (en) 2019-01-09 2022-08-10 Dana-Farber Cancer Institute, Inc. Dot1l degraders and uses thereof
JP2022523860A (ja) * 2019-03-11 2022-04-26 コラボレイティブ メディシナル デベロップメント， エルエルシー フェロトーシス関連障害の処置のための複素芳香族およびヘテロ二環式芳香族誘導体
CN110092804A (zh) * 2019-03-29 2019-08-06 广州盈升生物科技有限公司 一种含双环基团的嘌呤化合物及其制备方法
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
CN113024620B (zh) * 2021-03-11 2023-02-28 沈阳药科大学 一种嘌呤衍生物及其制备方法和用途
WO2022271540A1 (en) * 2021-06-21 2022-12-29 Mayo Foundation For Medical Education And Research Inhibitors of dot1l
CA3226162A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
AU2022316195A1 (en) * 2021-07-19 2024-01-04 Dana-Farber Cancer Institute, Inc. Targeting dot1l and smarca4/2 for the treatment of mllr leukemia

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20020127598A1 (en) 2000-03-27 2002-09-12 Wenqiang Zhou Solution-phase combinatorial library synthesis and pharmaceutically active compounds produced thereby
EP1138689A1 (en) 2000-03-28 2001-10-04 Roche Diagnostics GmbH N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization
EP1138688A1 (en) 2000-03-28 2001-10-04 Roche Diagnostics GmbH N8- and C8- linked purine bases as universal nucleosides used for oligonucleotide hybridization
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
WO2004007512A2 (en) * 2002-07-16 2004-01-22 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
NZ538457A (en) 2002-09-30 2008-04-30 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
GB0301450D0 (en) * 2003-01-22 2003-02-19 Medical Res Council Protein crystal structure
RU2354655C2 (ru) * 2003-12-19 2009-05-10 Ф.Хоффманн-Ля Рош Аг Ингибиторы сомт
SG155182A1 (en) 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US8058762B2 (en) * 2005-01-19 2011-11-15 Daikin Industries, Ltd. Rotor, axial gap type motor, method of driving motor, and compressor
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
EP1848718B1 (en) 2005-02-04 2012-08-01 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
WO2006113615A2 (en) 2005-04-15 2006-10-26 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof
CN106008512B (zh) 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
US8058258B2 (en) 2006-03-02 2011-11-15 Agency For Science, Technology And Research Methods for cancer therapy and stem cell modulation
GB0607953D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
US20080312160A1 (en) 2007-04-09 2008-12-18 Guerrant Richard L Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
CN101417967A (zh) 2007-10-26 2009-04-29 浙江海正药业股份有限公司 组蛋白去乙酰酶抑制剂、其组合物及其应用
PT2463282E (pt) 2007-11-05 2013-11-11 Novartis Ag Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
CA2711495A1 (en) 2008-01-09 2009-07-16 Pgxhealth Llc Intrathecal treatment of neuropathic pain with a2ar agonists
WO2010015643A1 (en) 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
US20110171192A1 (en) 2008-09-05 2011-07-14 Hiroshi Tomiyama Substituted amine derivative and medicinal composition comprising same as the active ingredient
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EA201290073A1 (ru) * 2009-08-24 2013-01-30 Эсэпиен Фармасьютикалз, Инк. Соединения мочевины, содержащие 5,6-бициклический гетероарил, как ингибиторы киназ
US8580762B2 (en) * 2010-12-03 2013-11-12 Epizyme, Inc. Substituted purine and 7-deazapurine compounds
AU2011336264A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds
CA2819625A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
CA2883781A1 (en) * 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
CA2903303A1 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
US10407732B2 (en) * 2013-08-02 2019-09-10 Memorial Sloan Kettering Cancer Center Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition
WO2015073706A1 (en) * 2013-11-13 2015-05-21 Epizyme, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
US20210252035A1 (en) 2021-08-19
CA2819648A1 (en) 2012-06-07
US20120142625A1 (en) 2012-06-07
EP2646444A1 (en) 2013-10-09
DK2646444T3 (da) 2016-06-27
US20140051654A1 (en) 2014-02-20
CN103391939A (zh) 2013-11-13
KR101923746B1 (ko) 2018-11-29
US20150366893A1 (en) 2015-12-24
ES2577027T3 (es) 2016-07-12
JP5931905B2 (ja) 2016-06-08
HK1189596A1 (zh) 2014-06-13
AU2011336415A1 (en) 2013-06-20
SI2646444T1 (sl) 2016-09-30
HRP20160655T1 (hr) 2016-09-23
TWI537271B (zh) 2016-06-11
TW201307348A (zh) 2013-02-16
BR112013013659A2 (pt) 2016-09-06
US9096634B2 (en) 2015-08-04
EP2646444B1 (en) 2016-03-16
IL226651A (en) 2016-11-30
WO2012075381A1 (en) 2012-06-07
US8580762B2 (en) 2013-11-12
CA2819648C (en) 2018-05-01
RU2013130250A (ru) 2015-01-10
KR20130125379A (ko) 2013-11-18
JP2013544846A (ja) 2013-12-19
US20180280422A1 (en) 2018-10-04
RU2606514C2 (ru) 2017-01-10
AU2011336415B2 (en) 2016-08-11
MX2013006251A (es) 2013-10-01
BR112013013659B1 (pt) 2022-06-21
CN103391939B (zh) 2016-03-09
AR084408A1 (es) 2013-05-15

Similar Documents

Publication Publication Date Title
BR112013013659B8 (pt) Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
GT201000015A (es) Sulfonamidas como moduladores de trpms
WO2012075492A3 (en) Carbocycle-substituted purine and 7-deazapurine compounds
BR112014003477A2 (pt) composições imunoterapêuticas de levedura-muc1 e usos das mesmas
WO2010041913A3 (ko) Grs 단백질 또는 이의 단편의 신규한 용도
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
BRPI0910388A2 (pt) agentes terapêutico antivirais.
CO6511271A2 (es) Compuestos de imidazopiridinil-aminopiridina sustituida
BR112013000107A2 (pt) aminopirazoloquinazolinas
BRPI0923786C1 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
BR112013022761B8 (pt) Compostos moduladores heterocíclicos de síntese de lipídios, suas composições e usos
UY33619A (es) Analogos de nucleotidos sustituidos
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
CL2015000851A1 (es) Compuestos derivados de piridina, inhibidores de gdf-8; composicion farmaceutica; metodo para tratar trastornos o enfermedades tales como distrofia muscular, osteoporosis, obesidad, diabetes tipo 2, tolerancia alterada de la glucosa, entre otras.
BR112015002152A2 (pt) pirróis substituídos ativos como inibidores de quinases
HK1213264A1 (zh) 经取代的苯化合物
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
BR112013003864A2 (pt) compostos de pirrolpirimidina e usos dos mesmos
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
BR112014013526A2 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2685 DE 21/06/2022, QUANTO AO ITEM (30) PRIORIDADE UNIONISTA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.